ATOS - アトッサ・ジェネティクス （Atossa Genetics Inc.）

Most of the biggest biotech stocks on the market started off as unknown penny stocks . Look at Axsome Therapeutics (NASDAQ: AXSM ), for example. At one time, it was a $2.50 stock. Now it’s up to $71 with a treatment for major depressive disorder. Fate Therapeutics (NASDAQ: FATE ) once traded at less than $2.50, and ran to more than $114. Novavax (NASDAQ: NVAX ) once traded around $3. All of them started small, but their strong pipelines didn’t let them stay cheap for long. In fact, find a biotech with hot data, an innovative way to treat an unmet medical need, or favorable reviews from the FDA, and you may just find the next big runner. However, remember, that biotech penny stocks can be risky. As noted by the U.S. Securities and Exchange Commission (SEC) , “Penny stocks may trade infrequently – which means that it may be difficult to sell penny stock shares once you have them. Because it may also be difficult to find quotations for penny stocks, they may be impossible to accurately price.

As with all speculative investments, today’s list of the best penny stocks under $1 should be approached with caution. Penny stocks are arguably one of the best ways to see outsized returns. They are also one of the most exciting. But they come with huge risks, and investors who fail to do their research are likely to fall prey to doomed or sham companies. Not all speculative ventures are created equal. Amid the sea of ultra-low-priced securities, only a handful of penny stocks shine. Here are three of the best penny stocks under $1. ATOS Atossa Therapeutics $0.74 INXSF Intouch Insight $0.34 WFSTF Western Forest Products $0.81 Atossa Therapeutics ( ATOS ) Source: luchschenF / Shutterstock.com Seattle-based Atossa Therapeutics (NASDAQ: ATOS ) is a clinical-stage biotech that focuses on treatments for breast cancer treatment and other breast-related conditions. Shares soared to insane heights shortly after going public in 2012, but shareholder value has been eroding for the past decade.

Typically, penny stocks are pure market wages for hardened gamblers. In fact, penny stocks are always risky — especially some of the best biotech stocks under $1 – and should oftentimes be avoided. And, as pointed out by the U.S. Securities and Exchange Commission (SEC) , “Penny stocks may trade infrequently – which means that it may be difficult to sell penny stock shares once you have them. Because it may also be difficult to find quotations for penny stocks, they may be impossible to accurately price. Investors in penny stock should be prepared for the possibility that they may lose their whole investment.” Granted, a few good ideas do pop up that may be worth throwing a few dollars at. But more often than not, penny stocks can lead to heavy losses. So, I always ask that you never risk more than you can afford to lose. That being said, I’ve uncovered some hot biotech penny stocks you may want to toss a few dollars at. Atossa Therapeutics, Inc ( ATOS ) Source: Shutterstock At 75 cents, Atossa Therapeutics, Inc. (NASDAQ: ATOS ) is rebounding from support of around 65 cents.

Atossa Therapeutics press release (ATOS): FY GAAP EPS of -$0.21 beats by $0.01.As of December 31, 2022, we had cash, cash equivalents and restricted cash of $111,000.Shares +2.53%.

SEATTLE, March 22, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in cancer, today announced financial results for the fiscal quarter and fiscal year ended December 31, 2022 and provided an update on recent company developments.

Atossa Therapeutics Inc. (NASDAQ:ATOS) closed Monday at $0.82 per share, down from $0.83 a day earlier. While Atossa Therapeutics Inc. has underperformed by -1.19%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ATOS fell by -33.86%, with highs and lows ranging from $1.62 to $0.50, whereas […]

While biotech may be the next big thing, making money through it isn’t easy. Indeed, investing in biotech stocks is often more of an art than a science. And considering these companies are solely focused on scientific endeavors, that’s not what many investors want to hear. For every Moderna (NASDAQ: MRNA ), which shot to wealth and fame on its MRNA-based COVID vaccine, there’s a CureVac (NASDAQ: CVAC ), another MRNA play, down 45% in the last year. Even the biggest biotech stocks, like Eli Lilly (NYSE: LLY ) and Johnson & Johnson (NYSE: JNJ ), can see their values hit hard by a single adverse decision from the Food and Drug Administration (FDA). This is the difference between today’s biotech and the last generation’s PC boom. Harmful drugs will kill you. They must undergo multiple rounds of expensive testing before they can be approved. Even approval is no guarantee of success. A safer play may be to buy an ETF like the iShares Biotechnology ETF (NASDAQ: IBB ), which is up 5% over the last year.

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Facts About: Atossa Therapeutics, Inc. (NASDAQ:ATOS -8.54%), Inseego Corp. (NASDAQ:INSG -13.50%) appeared first on Stocks Equity .

(ATOS) Constructed a change of -4.77% (Loss, ↓) in a total of its share price and finished it’s trading at 0.87. Atossa Therapeutics, Inc., belongs to Healthcare sector and Biotechnology industry. The company’s Market … The post Can Help Investors Wade Through Choppy Markets: Atossa Therapeutics, Inc. (NASDAQ:ATOS) Is in red zone with the indicator reading -4.77% appeared first on Stocks Equity .

As of Tuesday, Atossa Therapeutics Inc.’s (NASDAQ:ATOS) stock closed at $0.59, up from $0.53 the previous day. While Atossa Therapeutics Inc. has overperformed by 10.92%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ATOS fell by -63.36%, with highs and lows ranging from $1.80 to $0.50, […]

During the last session, Atossa Therapeutics Inc. (NASDAQ:ATOS)’s traded shares were 0.89 million, with the beta value of the company hitting 1.68. At the end of the trading day, the stock’s price was $0.53, reflecting an intraday gain of 1.32% or $0.01. The 52-week high for the ATOS share is $1.80, that puts it down … What To Expect As Atossa Therapeutics Inc. (NASDAQ: ATOS) Delivers An -47.67% Gain In 6 Months Read More »

Atossa Therapeutics Inc. (NASDAQ:ATOS) closed Wednesday at $0.50 per share, down from $0.52 a day earlier. While Atossa Therapeutics Inc. has underperformed by -2.73%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ATOS fell by -69.76%, with highs and lows ranging from $1.80 to $0.51, whereas […]

Atossa Therapeutics Inc. (NASDAQ:ATOS)’s traded shares stood at 0.35 million during the last session, with the company’s beta value hitting 1.66. At the close of trading, the stock’s price was $0.58, to imply an increase of 2.02% or $0.02 in intraday trading. The ATOS share’s 52-week high remains $1.85, putting it -218.97% down since that … Atossa Therapeutics Inc. (NASDAQ: ATOS): Can A Stock Be Down -64.01% YTD, And Still Be A Loser Read More »

Atossa Therapeutics Inc. (NASDAQ:ATOS) concluded the trading at $0.58 on Friday, December 16 with a fall of -0.38% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $0.59 and 5Y monthly beta was reading 1.65 with its price kept floating in the … Atossa Therapeutics Inc. (ATOS): Major Improvements, Worth A Look Read More »